GNRH1 and posterior cortical atrophy: Moreover, it was shown that, in PCa patients, switching from a GnRH agonist (goserelin or leuprolide) to another agonist (leuprolide or goserelin), after disease progression, is associated with a reduction of PSA levels [270].